Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PTC923 in phenylketonuria
2021-000474-29Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of sepiapterin in phenylketonuria (PKU) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Mean change in blood phenylalanine from baseline to Part 2 Weeks 5 and 6. Started Sep 2021; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2021-000474-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000474-29.